Method for diagnosing pulmonary artery hypertension
AssigneeUniversite Paris-Sud 11
InventorsLuc Mouthon, Marc Humbert, Mathieu Tamby
Life of this patent
Estimating the term…
Abstract
The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.
Claims20
An in vitro method for detecting pulmonary arterial hypertension (PAH), or a risk of developing PAH, which comprises determining the presence and/or the amount of anti-tenascin C antibodies in a biological sample originating from a patient, the presence of anti-tenascin C antibodies being indicative of PAH or a risk of developing PAH.
An in vitro method for the prognosis or the follow-up of PAH, which comprises determining the presence and/or the amount of anti-tenascin C antibodies in a biological sample originating from a patient, at various times, an increase in the amount of anti-tenascin C antibodies over time being indicative of a worsening of the PAH.
An in vitro method for evaluating the efficacy of a treatment for PAH, which comprises determining the presence and/or the amount of anti-tenascin C antibodies in a biological sample originating from a patient, at various times before, during or after the treatment, a decrease in the amount of anti-tenascin C antibodies over time being indicative of an improvement in the PAH.
Dependencies are inferred from the claim text.